A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer

N/ACompletedNCT05208268

Eisai Korea Inc.676 enrolled

Overview

The purpose of this study is to understand the following safety related particulars associated with the use of Pariet Tablet 5 milligram (mg) to prevent gastric and duodenal ulcer from low dose aspirin administration of 100 mg or less daily in participants with a history of gastric and duodenal ulcer: 1. Serious adverse events (SAEs) and adverse drug reactions (ADRs) 2. Unexpected adverse events (AEs) and ADRs not reflected in the precautions for use 3. Known ADRs 4. Non-serious ADRs 5. Other safety and efficacy related information.

Study Type

OBSERVATIONAL

Enrollment

676

Conditions

Stomach Ulcer Duodenal Ulcer

Interventions

ParietDRUG

Pariet Tablets.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Participants aged over 18 years 2. Participants who have a history of gastric and duodenal ulcer falling under the approved indication for Pariet Tablet 5 mg and who are receiving Pariet Tablet 5 mg to prevent gastric and duodenal ulcer from low dose aspirin use of 100 mg or less daily 3. Participants whose prescription of Pariet Tablet 5 mg has been determined before study participation 4. Participants who have given written consent to the use of their personal and medical information Exclusion Criteria: 1. Participants with a known hypersensitivity to rabeprazole sodium, any excipients used in the formulation or benzimidazole derivatives, and with the history of such hypersensitivity 2. Participants administered with atazanavir 3. Pregnant or lactating 4. Participants administered with rilpivirine 5. Participants currently participating in other clinical trials

Locations (29)

Site #09

Bucheon-si, Gyeongji-do, South Korea

Site #31

Bucheon-si, Gyeongji-do, South Korea

Site #24

Dongtan, Gyeongji-do, South Korea

Site #03

Ilsan, Gyeongji-do, South Korea

Site #11

Ilsan, Gyeongji-do, South Korea

Site #17

Incheon, Gyeongji-do, South Korea

Site #20

Changwon, Gyeongsangnam-do, South Korea

Site #29

Iksan, Jeollabuk-do, South Korea

Site #19

Cheongju-si, North Chungcheong, South Korea

Site #01

Chungju, North Chungcheong, South Korea

...and 19 more locations

Outcomes

Primary Outcomes

Percentage of Participants With SAEs

SAEs is defined as any untoward medical occurrence: resulting in death; life threatening condition requiring hospitalization or prolongation of hospitalization; resulting in persistent or significant disability or incapacity; resulting in birth defect or occurrence of other medically significant events that need treatment such as drug dependency or abuse, blood disease.

Time frame: Up to Week 24

Percentage of Participants With ADRs

Time frame: Up to Week 24

Percentage of Participants With Unexpected AEs

An AE is defined as any untoward and unintended signs (example, anomalies in laboratory test results), symptoms, or diseases occurring during administration of drug, which do not necessarily have a causal relationship with the drug in question. An unexpected AE is an AE with a difference in nature, severity, specificity, or outcome, compared to the product licensure/safety notification of the drug.

Time frame: Up to Week 24

Percentage of Participants With Unexpected ADRs

An ADR is defined as all noxious and unintended responses to a study drug related to any dose. All adverse events in which its causal relationship with the study drug is at least a reasonable possibility will be reported as ADR. An unexpected ADR is an ADR with difference in the nature or severity, specificity, or the outcome, compared to the product licensure/notification of the drug.

Time frame: Up to Week 24

Percentage of Participants With Already Known ADRs

An ADR is defined as all noxious and unintended responses to a study drug related to any dose. All adverse events in which its causal relationship with the study drug is at least a reasonable possibility will be reported as ADR. Already known ADRs are those listed in product licensure/notification of the drug.

Time frame: Up to Week 24

Percentage of Participants With Non-serious ADRs

Time frame: Up to Week 24

Percentage of Participants with Final Effectiveness Evaluation

Participants assessed for final effectiveness after first dose of drug will be categorized into four categories: Improved, Unchanged, Worsened, and Unknown.

Time frame: Up to Week 24